HIKMA PHARMACEUTICALS ORD GBP0.10
Symbol: HIK
Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Overview
Core Data
Latest Dividend Information
| Ex-Dividend Date | 21 Mar 2024 |
| Pay Date | 3 May 2024 |
| Total Dividends - Year to Date | 57.03 |
| Dividend Yield (%) | 3.1456 |
Historical Data & Ratios
| Avg Volume Over 10 Days | 0.5352 |
| Market Cap (M) | 4018.5730 |
| Price/Earnings (PE) | 26.8235 |
| Earnings Per Share | 67.59 |
| Revenue Per Share | 10.3755 |
| Return on Equity % | 8.7699 |
1 Month Performance Chart
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here |
0.35% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
N/A | N/A |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Charts
Company
Business Summary
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2023, Hikma Pharmaceuticals Plc revenues increased 14% to $2.88B. Net income increased 1% to $190M. Revenues reflect Generic Pharmaceuticals segment increase of 39% to $937M, Injectable Pharmaceuticals segment increase of 5% to $1.2B, Branded Pharmaceuticals segment increase of 3% to $714M, United States segment increase of 22% to $1.75B, Middle East and North Africa segment increase of 5% to $909M.
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
|---|---|---|---|---|---|---|
| Total Revenue | 2,875.00 | 2,517.00 | 2,553.00 | 2,341.00 | 2,203.00 | 2,076.00 |
| Gross profit | 1,407.00 | 1,265.00 | 1,301.00 | 1,213.00 | 1,095.00 | 1,072.00 |
| Operating Profit/Loss | 362.00 | 309.00 | 598.00 | 602.00 | 534.00 | 345.00 |
| Profit Before Tax | 281.00 | 233.00 | 544.00 | 558.00 | 491.00 | 293.00 |
| Profit After Tax | 192.00 | 191.00 | 420.00 | 430.00 | 487.00 | 285.00 |
| Equity Holders of Parent Company | 190.00 | 188.00 | 421.00 | 431.00 | 486.00 | 282.00 |
| Minority Interest | 9.00 | 10.00 | 15.00 | 14.00 | 11.00 | 9.00 |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 2,580.00 | 2,472.00 | 2,278.00 | 2,213.00 | 2,082.00 | 1,829.00 |
| Total Current Assets | 2,100.00 | 1,999.00 | 2,094.00 | 1,922.00 | 1,848.00 | 1,668.00 |
| Total Assets | 4,680.00 | 4,471.00 | 4,372.00 | 4,135.00 | 3,930.00 | 3,497.00 |
| Total Liabilities | 2,471.00 | 2,323.00 | 1,905.00 | 1,987.00 | 1,801.00 | 1,800.00 |
| Total Net Assets | 2,209.00 | 2,148.00 | 2,467.00 | 2,148.00 | 2,129.00 | 1,697.00 |
| Shareholders Funds | 2,198.00 | 2,135.00 | 2,453.00 | 2,135.00 | 2,117.00 | 1,685.00 |
| Minority Interests | 9.00 | 10.00 | 15.00 | 14.00 | 11.00 | 9.00 |
| Total Equity | 2,209.00 | 2,148.00 | 2,467.00 | 2,148.00 | 2,129.00 | 1,697.00 |
Outlook
Upgrades & Downgrades (Latest)
| Date | Broker | Recommendation | Price | Old Target | New Target | Change |
|---|---|---|---|---|---|---|
| 8th Apr 2024 | Barclays | Reiteration | 1839p | 0p | 2000p | Equal-weight |
| 26th Feb 2024 | Berenberg Bank | Reiteration | 1994p | 1960p | 2000p | Hold |
| 13th Nov 2023 | RBC Capital Markets | Reiteration | 1767p | 0p | 2150p | Sector perform |
| 16th Oct 2023 | JP Morgan Cazenove | Reiteration | 2069p | 0p | 0p | Overweight |
| 3rd Oct 2023 | Citigroup | Reiteration | 2053p | 0p | 0p | Buy |
| 12th Jul 2023 | Barclays | Reiteration | 1815p | 1700p | 1800p | Equal-weight |
| 22nd May 2023 | Jefferies | Reiteration | 1841p | 2080p | 2125p | Buy |
| 3rd May 2023 | Barclays | Reiteration | 1843p | 0p | 1700p | Equal-weight |
| 12th Apr 2023 | Jefferies | Reiteration | 1776p | 0p | 2080p | Buy |
| 9th Mar 2023 | JP Morgan Cazenove | Reiteration | 1789p | 0p | 2100p | Overweight |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
| Date | Time | Price | Volume | Type |
|---|---|---|---|---|
| 25 Apr 2024 | 18:08 | 1,839.506 | 5,822 | Sell |
| 25 Apr 2024 | 18:08 | 1,789 | 300 | Sell |
| 25 Apr 2024 | 18:06 | 1,842.104 | 31,753 | Sell |
| 25 Apr 2024 | 18:06 | 1,818.708 | 3,696 | Sell |
| 25 Apr 2024 | 17:53 | 1,804 | 228 | Sell |
| 25 Apr 2024 | 17:45 | 1,853.2 | 1,346 | Buy |
| 25 Apr 2024 | 17:45 | 1,853.972 | 1,878 | Buy |
| 25 Apr 2024 | 17:44 | 1,854.027 | 443 | Buy |
| 25 Apr 2024 | 17:44 | 1,853.815 | 10,526 | Buy |
| 25 Apr 2024 | 17:44 | 1,853.97 | 135 | Buy |
| 25 Apr 2024 | 17:44 | 1,865.253 | 253 | Buy |
| 25 Apr 2024 | 17:43 | 1,817.875 | 8 | Sell |
| 25 Apr 2024 | 17:43 | 1,838.809 | 372 | Sell |
| 25 Apr 2024 | 17:42 | 1,828.667 | 3 | Sell |
| 25 Apr 2024 | 17:42 | 1,841.562 | 89 | Sell |
| 25 Apr 2024 | 17:42 | 1,805.428 | 1,042 | Sell |
| 25 Apr 2024 | 17:42 | 1,750.182 | 22 | Sell |
| 25 Apr 2024 | 17:39 | 1,854 | 244 | Buy |
| 25 Apr 2024 | 17:36 | 1,806.642 | 104 | Sell |
| 25 Apr 2024 | 17:36 | 1,835.854 | 4,661 | Sell |
Selected data supplied by Thomson Reuters © View restrictions.